Asparaginase Pharmacokinetics After Intensive Polyethylene Glycol-Conjugated L-Asparaginase Therapy for Children with Relapsed Acute Lymphoblastic Leukemia

S. Hawkins, Douglas; R. Park, Julie; Thomson, Blythe; Felgenhauer, Judy; S. Holcenberg, John; H. Panosyan, Eduard; I. Avramis, Vassilios

doi:10.1158/1078-0432.ccr-04-0222

Public

Asparaginase Pharmacokinetics After Intensive Polyethylene Glycol-Conjugated L-Asparaginase Therapy for Children with Relapsed Acute Lymphoblastic Leukemia

Published in Clinical Cancer Research • Aug 15, 2004

Authors:

Douglas S. Hawkins

Julie R. Park

Blythe Thomson

Abstract

PURPOSE: Asparaginase therapy is an important component in the treatment of children with acute lymphoblastic leukemia. Polyethylene glycol-conjugated asparaginase (PEG-ASNase) has significant pharmacological advantages over native Escherichia coli asparaginase. We investigated the pharmacokinetics ...

Subject

Asparaginase

Medicine

PEG ratio

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!